| Title |
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis
|
|---|---|
| Published in |
Annals of Surgical Oncology, December 2017
|
| DOI | 10.1245/s10434-017-6313-5 |
| Pubmed ID | |
| Authors |
Johan Gagnière, Julie Veziant, Bruno Pereira, Denis Pezet, Bertrand Le Roy, Karem Slim |
| Abstract |
Whether cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is safe and worthwhile for elderly patients remains unclear. This meta-analysis of outcomes after CRS plus HIPEC for the elderly aimed to generate a higher level of evidence and precise indications for these patients. A systematic literature search for studies reporting postoperative outcomes after CRS plus HIPEC for elderly patients was performed in the MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, Web of Knowledge Conference Proceedings Citation Index-Science, and Google Scholar databases. The included studies evaluated the overall 30-day postoperative morbidity, 90-day postoperative mortality, grade 3 or higher postoperative morbidity, rates of anastomotic leaks, reoperation and readmission, and length of hospital stay. The inclusion criteria were met by 13 retrospective studies involving 2544 patients. Considering only comparative studies, the 90-day postoperative mortality was significantly increased for elderly patients [odds ratio (OR), 0.49; 95% confidence interval (CI), 0.27-0.88; I 2 = 79%]. The 30-day grade 3 or higher postoperative morbidity was increased in the patients 70 years of age or older (14.5%; 95% CI 8.1-24.4 vs. 32.3%; 95% CI 22.4-44.0%; p = 0.004; I 2 = 85%). The overall 30-day postoperative morbidity, rates of anastomotic leaks, reoperation and readmission, and length of hospital stay were not affected by age. Treatment of the elderly with CRS plus HIPEC was associated with increased severe postoperative morbidity and mortality. However, these conclusions should be weighted given the existence of major biases in the included studies. Age alone probably would not be a formal contraindication, but frailty should be taken into account. Further prospective studies are needed. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 26% |
| Spain | 2 | 11% |
| Mexico | 2 | 11% |
| South Africa | 1 | 5% |
| Italy | 1 | 5% |
| Unknown | 8 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 63% |
| Practitioners (doctors, other healthcare professionals) | 4 | 21% |
| Scientists | 3 | 16% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor > Associate Professor | 4 | 11% |
| Other | 4 | 11% |
| Researcher | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Student > Master | 3 | 8% |
| Other | 6 | 17% |
| Unknown | 11 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 44% |
| Nursing and Health Professions | 2 | 6% |
| Business, Management and Accounting | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 11 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2018.
All research outputs
#3,255,516
of 25,084,886 outputs
Outputs from Annals of Surgical Oncology
#879
of 7,161 outputs
Outputs of similar age
#69,524
of 454,170 outputs
Outputs of similar age from Annals of Surgical Oncology
#14
of 91 outputs
Altmetric has tracked 25,084,886 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,161 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,170 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.